FDA supports tighter restrictions on hydrocodone
WASHINGTON — The Food and Drug Administration is recommending tighter restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the United States.
In a major policy shift, the agency said in an online notice on Thursday that hydrocodone-containing drugs should be subject to the same restrictions as other narcotic drugs such as oxycodone and morphine.
More than a decade has passed since the Drug Enforcement Agency asked the FDA to reclassify hydrocodone so that it would be subject to the same restrictions as other opioid drugs. The FDA did not issue a formal announcement about its decision, which has long been sought by many patient advocates, doctors and lawmakers.
In early December, the FDA says it will formally request that hydrocodone be classified as a Schedule II drug, limiting who can write a prescription and how many times it can be refilled.
Show commenting policy
TribLive commenting policy
- Obama defers deportations for 4 million illegals
- Former Va. Sen. Webb launches presidential exploratory committee
- NSA: China thefts could lead to attack
- Ex-coal exec pleads not guilty in W.Va. mine blast
- Enrollment count in federal health care law padded, House panel says
- GOP hopes backlash doesn’t backfire
- FDA approves Hysingla painkiller’s abuse deterrent form
- 4 Yemenis, Tunisian moved from Gitmo
- Shooter wounds 3 in Florida State library before being killed by police
- Giant nutcracker will stand 41 feet
- E-cigarettes cut cravings, study finds